Sector Expert: Karen Bulock

RXi Pharmaceuticals Corp.

Dr. Karen Bulock has served as vice president research for RXi Pharmaceuticals since April 2012. Dr. Bulock has over 20 years of experience in discovery and preclinical project management. Since joining RXi in 2011, Dr. Bulock has been responsible for strategy and execution of RXi's discovery and preclinical research projects including RXI-109, RXi's first clinical candidate. Prior to joining RXi, Dr. Bulock served as the associate director of research at Galena Biopharma. Prior to Galena, she spent several years leading discovery-stage projects to support small molecule therapeutic programs in the fields of metabolic disease and anti-infectives at CytRx Corp. and Essential Therapeutics Inc. Dr. Bulock received a Ph.D. in Pharmacology from Yale University. Dr. Bulock has authored numerous scientific articles and is a co-inventor on many patent applications.



Recent Interviews

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End (10/4/17)
rnai-cover

With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.



Due to permission requirements, not all quotes are shown.